Tokyo, June 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061975) titled 'Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection:a multicenter, randomized, controlled trial' on June 19.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Akashi Medical Center

Condition: Condition - upper respiratory tract infection Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - We investigate the efficacy of tranexamic acid on sore throat pain associated with acute URTI compared with a placebo. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Patients receive 1g of 50% tranexamic acid preparation three times a day. Interventions/Control_2 - Patients receive 1g placebo (lactose) three times a day.

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients of upper respiratory tract infections with a complaint of sore throat, who visited a general internal medicine department office in trial hospital from July 2026 to March 2027 were registered. Key exclusion criteria - Patients with allergy to tranexamic acid and lactose, pregnant patients or patients with possibility of pregnancy, breastfeeding patients, patients who take tranexamic acid, patients who were unable to participate the study because of dementia, visual impairment and unable to answer, or complete the study form. Target Size - 100

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 06 Month 19 Day Date of IRB - 2026 Year 06 Month 11 Day Anticipated trial start date - 2026 Year 07 Month 13 Day Last follow-up date - 2027 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070917

Disclaimer: Curated by HT Syndication.